A solid reputation.
Novo Nordisk has been dedicated to growth hormone therapy for over 40 years. Today, Norditropin® (somatropin [rDNA origin] injection) helps people in over 80 countries around the world.
- Novo Nordisk launched its first growth hormone product, called Nanormon®, in 1973.
- Norditropin® was first approved for use in the United States in 1995 by the Food and Drug Administration (FDA).
- Norditropin® helps people in over 80 countries around the world.
You’re not the 1st – or even the 1001st.
Your family isn’t the first to deal with a child’s growth hormone-related disorder. Over 43,000 patients have been treated with Norditropin® since 2003.